Greta Garrido
Chief Executive Officer & Co-Founder Sebastian BioPharma
Greta Garrido, PhD, is the CEO and Co-Founder of Sebastian Biopharma, a preclinical-stage biotechnology company pioneering targeted RNAi therapeutics to enhance tumor antigenicity and overcome resistance to immunotherapy. With over 15 years of experience in immuno-oncology, she has held leadership roles at Gritstone bio, Nurix Therapeutics, and BlueSphere Bio, specializing in TCR discovery, cell therapy, and translational research. Dr. Garrido previously developed RNA oligonucleotide bioconjugates at the University of Miami, laying the foundation for Sebastian’s modular antibody-oligonucleotide platform. She holds a PhD and has contributed extensively to high-impact publications and patents in cancer immunotherapy.
Seminars
- Showcasing early preclinical evidence of tumor-selective siRNA activity with minimized off-target effects through aptamer-based targeting
- Introducing the Antibody-Oligonucleotide Conjugate (AOC) platform and proof-ofconcept studies validating precision tumor delivery
- Presenting data from lead candidate selection and in-depth characterization to demonstrate potency and durability
- Exploring future opportunities to integrate Sebastian BioPharma’s RNAi platforms with checkpoint inhibitors and precision medicine strategies to expand patient benefit
